Within the realm of targeted therapy, EGFR stands as a quintessential model: activating mutations found in the EGFR gene are widespread among a significant portion of individuals afflicted with NSCLC, and can be effectively targeted by TKIs such as erlotinib, gefitinib, and osimertinib, which have markedly improved PSF and OS of many patients (306). Here, EGFR is linked to non-small cell lung carcinoma.